Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo
International Journal of Dermatology · 2026-09 · 65 (9) · 1953-1954
DOI: 10.1111/ijd.70367 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, online erschienen am 25.02.2026. Verfasst von Federico Venturi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
- Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy.
- Department of Dermatology & Venereology, University Hospital Center "Mother Teresa", Tirana, Albania.
- Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Federico Venturi, Emi Dika
Zitieren
APA
Venturi, F., Sotiri, I., Melotti, B., Fida, M., & Dika, E. (2026). Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo. International Journal of Dermatology, 65(9), 1953-1954. https://doi.org/10.1111/ijd.70367
Vancouver
Venturi F, Sotiri I, Melotti B, Fida M, Dika E. Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo. International Journal of Dermatology. 2026;65(9):1953-1954. doi:10.1111/ijd.70367
BibTeX
@article{Venturi2026,
author = {Venturi, Federico and Sotiri, Ina and Melotti, Barbara and Fida, Monika and Dika, Emi},
title = {Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {9},
pages = {1953--1954},
doi = {10.1111/ijd.70367}
}
EUVIMED